Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.

ABSTRACT:

Background

In this post hoc analysis, we assessed patient characteristics as predictors of dronedarone trough concentrations and characterized the relationship of trough concentrations of dronedarone with its efficacy and safety.

Hypothesis

Dronedarone is recommended as a 400 mg twice daily dose taken orally with meals. We hypothesize that drug concentration/bioavailability of dronedarone, measured as above- and below-median trough concentrations, does not impact the efficacy outcomes.

Methods

Average trough concentrations (C_{trough_avg} ) across multiple timepoints were calculated for each patient, and patient C_{trough_avg} values were categorized as below-median or above-median concentrations. The effect of patient baseline characteristics on drone

SUBMITTER: Thind M 

PROVIDER: S-EPMC8799059 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature